FBT

First Trust NYSE Arca Biotechnology Index Fund

Current Price
$268.15
Market Cap
$2.89 B
RETURN (12M)
49.60%
RETURN (5Y)
57.91%
DY
0.00%
Price

FBT PRICE

Select period
Select period
First Trust NYSE Arca Biotechnology Index Fund
If you had invested
If you had invested
exposure
years ago
7 days
30 days
6 months
YTD
1 year
5 years
10 years
15 years
ago, you would now have *
ago, you would now have:
*
*This calculation reflects price variation only.

Return on Investment FBT

1 month
3 months
1 year
2 years
5 years
10 years
return
1 month
-1.03%
3 months
16.69%
1 year
49.60%
2 years
57.15%
5 years
57.91%
10 years
166.87%
Price

Stock vs Indice Comparison Tool

If you had invested
If you had invested
years ago
2 years
5 years
10 years
ago, you would now have *
ago, you would now have:
*
*This calculation reflects price variation only.
Price

First Trust NYSE Arca Biotechnology Index Fund Historical Dividends

current DY: 0.00%

5-year average DY: 0.83%

DRAG THE FRAME TO SEE MORE DATA

type

Ex - Dividend Date

payment date

value

Dividends 12/13/2024 12/31/2024 1.17300000
Dividends 12/31/2021 01/10/2022 2.21400000
Dividends 09/25/2015 09/30/2015 0.01970000
Dividends 06/26/2015 06/30/2015 0.06490000
Dividends 03/27/2015 03/31/2015 0.04760000
Dividends 12/26/2014 12/31/2014 0.05240000
Dividends 06/25/2008 06/30/2008 0.26970000
Composição

ETF COMPOSITION FBT

Company name Ticker Asset type Sector Market cap % in ETF
HALO Stock Healthcare US$ 12.51 B 4,34%
NEO Stock Healthcare US$ 2.23 B 3,94%
RGEN Stock Healthcare US$ 9.46 B 3,90%
CORT Stock Healthcare US$ 12.07 B 3,83%
BGNE Stock Healthcare US$ 20.21 B 3,74%
REGN Stock Healthcare US$ 86.84 B 3,74%
NTRA Stock Healthcare US$ 47.23 B 3,70%
AMGN Stock Healthcare US$ 240.11 B 3,67%
ARGX Stock Healthcare US$ 65.51 B 3,65%
GMAB Stock Healthcare US$ 133.07 B 3,55%
GILD Stock Healthcare US$ 187.51 B 3,50%
ILMN Stock Healthcare US$ 32.95 B 3,49%
VRTX Stock Healthcare US$ 141.42 B 3,48%
BNTX Stock Healthcare US$ 26.06 B 3,45%
SRPT Stock Healthcare US$ 2.43 B 3,45%
BMRN Stock Healthcare US$ 12.86 B 3,43%
BIIB Stock Healthcare US$ 32.63 B 3,38%
INCY Stock Healthcare US$ 25.69 B 3,28%
ADMA Stock Healthcare US$ 2.15 B 3,21%
TECH Stock Healthcare US$ 11.36 B 3,15%
MDGL Stock Healthcare US$ 12.54 B 3,13%
EXEL Stock Healthcare US$ 14.62 B 3,00%
BRKR Stock Healthcare US$ 9.05 B 3,00%
TGTX Stock Healthcare US$ 8.57 B 2,95%
UTHR Stock Healthcare US$ 20.91 B 2,90%
ALKS Stock Healthcare US$ 7.73 B 2,81%
NBIX Stock Healthcare US$ 15.82 B 2,70%
AXSM Stock Healthcare US$ 10.91 B 2,64%
ALNY Stock Healthcare US$ 35.78 B 2,50%
VCYT Stock Healthcare US$ 3.42 B 2,36%

ABOUT

First Trust NYSE Arca Biotechnology Index Fund

Average Investor10 user rating

4.0 (7 people)

Frequently Asked Questions

What is the price of FBT today?

The current price of FBT is $268.15. You can track the real-time price chart, review historical performance, and access detailed information about this ETF on the platform.

Is FBT a good investment?

FBT is currently trading at $268.15, with a market capitalization of approximately $2.89 billion. Over the past year, the ETF has delivered a 49.60% return, based on share price performance.

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

How can I buy shares of FBT?

You can invest in FBT through a brokerage account that provides access to the exchange where it is listed. After opening and funding your account, search for the ticker symbol FBT, select the number of shares you wish to purchase, and place your order.

In certain markets, similar exposure may also be available through locally listed products that track the same index.

How much would 100 shares of FBT be worth today?

Over the past month, FBT has returned -1.03%, and 49.60% over the past year.

If you were to purchase 100 shares of FBT at the current price of $268.15, your total investment would be $26,815.00.

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.